Pharmanest appoints Alan Raffensperger as Chairman of the Board
Stockholm, November 1, 2012. Today Pharmanest AB, a Karolinska Development portfolio company, announced that Alan Raffensperger, Per Langö and Gunilla Ekström have been elected as new members of the Board. Alan Raffensperger was elected Chairman. The Board of Pharmanest has hereby gained comprehensive experience in the commercialization of new, innovative products and is well prepared to progress the candidate drug SHACT, for pain relief in gynecological procedures.Alan Raffensperger has extensive international experience in management, business development and strategic planning in the